Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 7:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2665–2688 of 6,928 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Stimulation Clear all

Conditions: Cannabis Use, Cannabis Use Disorder
Interventions: Magstim SuperRapid2, Sham rTMS; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 15 Years to 21 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Leukemia
Interventions: filgrastim, cladribine, idarubicin; Biological · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2007
U.S. locations: 206
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Pioglitazone, Placebo, Pancreatic Clamp Study; Drug · Procedure
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2011
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Interventions: Sham Intervention, Survey Administration, Transcranial Direct Current Stimulation; Procedure · Other · Device
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 60 Years to 85 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Brain Tumors, Transcranial Magnetic Stimulation, Motor Deficit, Quality of Life
Interventions: Transcranial magnetic stimulation (TMS); Device
Lead sponsor: Brian J.Gill; Other
Eligibility: 22 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Perinatal Brain Injury
Interventions: Constraint-Induced Movement Therapy (CIMT), Transcutaneous auricular vagus nerve stimulation (taVNS); Behavioral · Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 8 Months to 24 Months
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Stroke, Aphasia, Language
Interventions: Transcranial Magnetic Stimulation; Device
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 85 Years
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2032
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Depersonalization Disorder
Interventions: Repetitive Transcranial Magnetic Stimulation (rTMS); Device
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD), rTMS, Ketamine, fMRI
Interventions: TMS, Ketamine; Device · Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: New York, New York

Conditions: Anemia
Interventions: Methoxy Polyethylene Glycol-Epoetin Beta, Epoetin alfa, Epoetin beta, Darbepoetin alfa; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 83
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 69 more

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: Neuromuscular electrical stimulation; Device
Lead sponsor: University of Vermont Medical Center; Other
Eligibility: 50 Years to 90 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Stroke, Hemiparesis, Footdrop
Interventions: Contralaterally Controlled Neuromuscular Electrical Stimulation, Cyclic Neuromuscular Electrical Stimulation; Device
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 21 Years to 75 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Recurrent Glioblastoma
Interventions: Pembrolizumab, SurVaxM, Sargramostim, Montanide ISA 51; Drug
Lead sponsor: David Peereboom; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Chronic Refractory Pain Associated With Failed Back Surgery Syndrome, Epidural Fibrosis, Peripheral Causalgia, Complex Regional Pain Syndrome
Interventions: Spinal Cord Stimulation; Device
Lead sponsor: MedtronicNeuro; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 8
States / cities: Chicago, Illinois • Indianapolis, Indiana • Kansas City, Missouri + 5 more

Conditions: Rupture of Anterior Cruciate Ligament
Interventions: cryotherapy, TENS; Other
Lead sponsor: University of Virginia; Other
Eligibility: 15 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Logopenic Variant Primary Progressive Aphasia, Non-Fluent Primary Progressive Aphasia
Interventions: Active rTMS, SHAM rTMS; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 90 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatocellular Carcinoma
Interventions: Regorafenib 40 MG; Drug
Lead sponsor: SC Liver Research Consortium, LLC; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 9
States / cities: Gilbert, Arizona • Long Beach, California • New Orleans, Louisiana + 6 more

Conditions: Schizophrenia and Related Disorders
Interventions: Active rTMS stimulation, Sham rTMS stimulation; Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 60 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Stroke
Interventions: Device-assisted therapy, Therapy-based occupational therapy; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Baltimore, Maryland • New York, New York

Conditions: Diabetes Mellitus, Type 1
Interventions: Anti-Thymocyte Globulin (ATG), Granulocyte colony stimulating factor (GCSF), Placebo (for ATG), Placebo (for GCSF); Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 12 Years to 45 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 13
States / cities: San Francisco, California • Stanford, California • Aurora, Colorado + 10 more

Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally Advanced Oropharyngeal Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions: Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Pembrolizumab, Computed Tomography, FDG-Positron Emission Tomography, Biospecimen Collection, Biopsy; Biological · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Parkinson Disease
Interventions: N-0923; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neuropathic Pain
Interventions: Not listed
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Spinal Cord Injury
Interventions: Transcranial direct current stimulation + step training, Sham transcranial direct current stimulation + step training; Device · Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Transcranial Magnetic Stimulation for Adolescents and Young Adults With Cannabis Use Disorder

Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia

The Role of Acute Combined PPAR Alpha and Gamma Stimulation on Insulin Action in Humans

Transcranial Direct Current Stimulation to Improve Gait for Breast Cancer Survivor's Who Received Taxene and/or Platinum Chemotherapy

rTMS for Postoperative Brain Tumor Patients

Neuro-MoD: Neuroplasticity With Motor Development

Language Processing and TMS

Treatment of Depersonalization Disorder With Transcranial Magnetic Stimulation (TMS)

Biomarker-Guided Antidepressant Selection

A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia

NMES in HF Patients to Improve Functional Recovery Following Hospitalization

Functional Electrical Stimulation Mediated Neuroplasticity: Lower Extremity CCNMES in Stroke

Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

Restore Claims Characterization Study

Quadriceps Function Prior to Anterior Cruciate Ligament Reconstruction

rTMS as a Treatment for PPA

Optimization for Regorafenib in HCC

Bilateral Prefrontal and Insular TMS for Depression in Schizophrenia

Study to Enhance Motor Acute Recovery With Intensive Training After Stroke

ATG-GCSF in New Onset Type 1 Diabetes

A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

Treatment of Parkinson's Disease With a Transdermal Skin Patch

Brain Connectivity Changes With Spinal Cord Stimulation and Treatment of Chronic Pain: A Resting State NIRS/EEG Study

Skilled Motor Training and tDCS to Improve Leg Function After Spinal Cord Injury